AstraZeneca ’s Lynparza shows positive outcome in Phase III trial for ovarian cancer

AstraZeneca has reported positive findings from the Phase III SOLO-2 clinical trial of Lynparza (olaparib) to treat patients with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news